Walleye Capital’s Century Therapeutics IPSC Stock Holding History

Walleye Capital’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-152,796	Closed	-$784K	–	4148
2022 Q4	$784K	Buy	152,796 +26,233	+21%	+$248K	0.01%	1146
2022 Q3	$1.25M	Buy	126,563 +47,865	+61%	+$504K	0.02%	819
2022 Q2	$661K	Buy	78,698 +27,790	+55%	+$273K	0.02%	855
2022 Q1	$641K	Sell	50,908 -11,563	-19%	-$153K	0.02%	880
2021 Q4	$991K	Buy	+62,471	New	+$1.17M	0.03%	601

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's IPSC Position: Q1 2023 in Review

Walleye Capital sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 152,796 shares — an estimated $784K sold.

Walleye Capital first reported a position in IPSC in Q4 2021 and held it in 5 quarters. The position peaked at $1.25M in Q3 2022. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

Walleye Capital reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 152,796 Century Therapeutics shares in Q1 2023, an estimated $784K.
Walleye Capital first reported a position in Century Therapeutics in Q4 2021 and held it in 5 quarters.
Walleye Capital's Century Therapeutics position peaked at $1.25M in Q3 2022.
63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.